Skip to content

New Intraoperative Nerve Monitoring Device

Evaluation of the Usability and Safety of the Newly Developed Piezoelectric Sensor Intraoperative Nerve Monitoring Device in Thyroid and Parathyroid Surgery: A Pilot Study

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07071571
Acronym
IONM
Enrollment
40
Registered
2025-07-17
Start date
2025-08-01
Completion date
2026-12-01
Last updated
2025-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thryoid Cancer, parathyrıoid Adenoma

Keywords

neuromonitorization, introperative, recurrent nerve, new device

Brief summary

This study is testing a new device developed to protect the recurrent laryngeal nerve, which is at risk of damage during thyroid and parathyroid surgeries.

Detailed description

This study is testing a new device developed to protect the recurrent laryngeal nerve, which is at risk of damage during thyroid and parathyroid surgeries. Such devices are still used in surgical routine, but research has been initiated on this subject due to the higher sensitivity and reliability of this new device.

Interventions

new neuromonitorin device will use

Sponsors

SB Istanbul Education and Research Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Masking description

no masking

Intervention model description

Recurrent nerve monitoring will be performed in patients with thyroid or parathyroid surgery indications.

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-70, diagnosis of benign/malignant thyroid disease, informed consent

Exclusion criteria

* History of previous nerve injury, concomitant neurological disorder

Design outcomes

Primary

MeasureTime frameDescription
recurrent nerve identificationintroperativelynerve will be identified with new device

Contacts

Primary Contacterhan aysan, MD Prof
erhanaysan@hotmail.com+902165785000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026